The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment.
With interest rates once again dropping as the geopolitical worries ratchet up, investors are concerned about owning good stocks and receiving dependable dividends. One place that looks very good now is pharmaceuticals.
The March 31 short interest data have been compared with the previous figures, and short interest decreased in most of these selected pharmaceutical stocks.
Several analysts and market pundits have been positive toward Eli Lilly lately, including now a price target raise at JPMorgan.
Jon C. Ogg The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.
Eli Lilly released a mixed fourth-quarter earnings report and offered full-year guidance before the markets opened on Tuesday.
Chris Lange 24/7 Wall St. has put together a preview of some of the major companies reporting on Tuesday, including Apple and two other Dow stocks.
The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly down.
Trump said last week that companies in the health care sector are “getting away with murder,” and that something had to change. The sector has pulled back slightly since then, but there…
This acquisition not only will enhance Eli Lilly's existing portfolio in pain management for migraine, but it also adds a potential near-term launch to its late-stage pipeline.
Trey Thoelcke The top analyst upgrades, downgrades and initiations seen on Tuesday include American Express, JPMorgan, Netflix, Nordstrom and Twitter.
